Erratum in Schmidt et al., Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia

SR indicates standard risk; NAD, nothing abnormal detected in the above assays; LR, low risk; MR, medium risk; IR, intermediate risk; DBA, died before risk assignment; HR, high risk; ND, not done; and NA, not applicable.

Risk group assignment according to the BFM 2000 protocol (BFM-ALL Study Group): SR indicates standard risk (prednisolone good response, as well as complete cytomorphologic bone marrow remission on day 33, and neither BCR/ABL nor MLL/AF4, and MRD-negative on day 33); MR, medium risk (as standard but MRD-positive on day 33); HR, high risk (prednisolone poor response or BCR/ABL or MLL/AF4 or MRD-positive on day 77).

Molecular diagnosis included ploidy determination by standard karyotyping, detection of BCR/ABL, E2A/PBX1, MLL-1/AF-4, TEL/AML, SIL/TAL translocations by PCR and reconfirmation by in situ hybridization.

Risk assignment according to MRD (minimal residual disease) detection by T-cell receptor or immunoglobulin rearrangement-specific PCR.

CD marker expression in 80% or more of blasts as determined by direct immunofluorescence and FACS analysis.

Entity assignment by gene clustering according to Ross et al³³ (Figure S2).

GC bioactivity in nM cortisol equivalents: means of 2 measurements at 0, 6, and 24 hours.

Data derived from expression profiling only.